cerebral spinal fluid Archives - Halberd Corporation

Feb 22 2022

Halberd Medical Breakthrough for the Treatment of Neurodegenerative Diseases Affecting 36 Million Americans Annually

By Admin|2022-02-21T18:59:51-05:00February 22nd, 2022|Featured, Investor News, Medical, News, Press Releases|1 Comment

Jackson Center, PA, February 22, 2022 – Halberd Corporation (OTC PINK:HALB) has made a medical breakthrough in the treatment of neurodegenerative diseases. With the successful elimination of glutamate from cerebral spinal fluid (CSF), Halberd has demonstrated the capability to control each of the top ten neurodegenerative disease-associated antigens. See Table Below. This could lead to ...

Dec 20 2021

Halberd Moves Closer to Proving Its Patented Technologies Eliminate Contributors to Neurodegenerative Diseases

By Admin|2021-12-19T18:05:14-05:00December 20th, 2021|Investor News, Medical, News|0 Comments

Latest Testing Eliminates Interleukin-2 From Cerebral Spinal Fluid Jackson Center, PA, December 20, 2021 – Halberd Corporation (OTC PINK:HALB) has been able to successfully eliminate Interleukin-2 (IL-2) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Halberd has also completed confirmatory tests on the elimination of all the previously tested cytokines (see table below). Interleukin-2 ...

Dec 13 2021

Halberd Successfully Eradicates Interluekin-1 in Its Continued Progress Toward Eliminating Neurodegenerative Diseases

By Admin|2021-12-12T18:23:45-05:00December 13th, 2021|Featured, Investor News, Medical, News, Press Releases|0 Comments

Jackson Center, PA, December 13, 2021 – Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Interleukin-1 is associated with numerous diseases ranging from autoimmune to Multiple Sclerosis and Alzheimer’s Disease. Halberd’s demonstrated ability to control the levels of IL-1, coupled with its previous ...

Dec 6 2021

Halberd Follow-up Verification Tests Prove 100% Eradication of TNF-alpha, a Major Contributing Factor to Alzheimer’s Disease and PTSD/CTE

By Admin|2021-12-05T19:03:46-05:00December 6th, 2021|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, December 6, 2021 – Halberd Corporation (OTC PINK:HALB) completed verification tests on elimination of Tumor Necrosis Factor-alpha (TNF-alpha) from synthetic cerebral spinal fluid (CSF). These tests confirmed virtually 100% elimination of TNF-alpha through Halberd’s patented extracorporeal process, in combination with its patent-pending exposure to tuned laser irradiation. TNF-alpha is an inflammatory cytokine ...

Nov 22 2021

Halberd Successfully Eradicates TNF-α, a Major Contributing Factor to Alzheimer’s Disease

By Admin|2021-11-21T20:32:25-05:00November 22nd, 2021|Investor News, News, Press Releases|0 Comments

Halberd Successfully Eradicates TNF-α, a Major Contributing Factor to Alzheimer’s Disease Jackson Center, PA, November 22, 2021 – Halberd Corporation (OTC PINK:HALB) successfully eradicated 85% of Tumor Necrosis Factor-alpha (TNF-α) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Through Halberd’s patented extracorporeal process, in combination with its patent-pending laser eradication methodology, TNF-α was eliminated ...

Nov 1 2021

Halberd Successfully Eradicates IL-6, a Critical Factor in PTSD, CTE & Alzheimer’s Disease

By Admin|2021-10-31T17:47:07-04:00November 1st, 2021|Featured, Investor News, Medical, News|0 Comments

Elevated levels of IL-6 are believed to be causal factors in PTSD, Chronic Traumatic Encephalopathy, & Alzheimer’s Disease. Jackson Center, PA, November 1, 2021 – Halberd Corporation (OTC PINK:HALB) successfully eradicated 100% of IL-6 from synthetic cerebral spinal fluid (CSF) in preliminary testing. Through its patented extracorporeal process in combination with its patent-pending laser eradication ...

Jul 28 2021

Halberd Corporation Successfully Establishes Disease Eradication Proof-of-Concept – “Never Before Accomplished”

By Admin|2021-07-27T17:35:26-04:00July 28th, 2021|Featured, Investor News, News|0 Comments

A Major Step Towards the Elimination of Multiple Infectious Diseases and Possible Treatment for Alzheimer’s Disease/PTSD/CTE Jackson Center, PA, July 28, 2021 – Halberd Corporation (OTC-PINK: "HALB") establishes “proof of concept” taking a major step towards the elimination of multiple infectious diseases, such as, malaria, tuberculosis, sepsis, meningitis, and pandemics, among others, by successfully eliminating ...

Jun 16 2021

Halberd Corporation Successfully Conjugates Metallic Particles and Antibodies Against Alzheimer’s Disease-Associated Antigens

By Admin|2021-06-15T21:04:24-04:00June 16th, 2021|Featured, Investor News, News|0 Comments

Enables Extracorporeal Eradication of Pathogens from Cerebral Spinal Fluid Via Radio Frequency and/or Laser Emissive Energy Jackson Center, PA, June 16, 2021 – Halberd Corporation (OTC-PINK: "HALB") has successfully conjugated, Tau, Phosphorylated Tau and Beta Amyloid antibodies with gold-coated iron oxide nanoparticles in a patent-pending process. These three antigens, which are found in Cerebral Spinal ...